Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (3262)	4/1/2001 4:41:23 PM
From: dalroi	Respond to of 52153

well one in the same category from the wall street journal o tempora o mores no wonder nobody gets a grip on biotech Merrill's Mr. Wilson suggests MedImmune , which makes a vaccine used to fight infant pneumonia. The drug accounts for the majority of the company's sales and will give it 30% earnings growth for the next few years, he says. While MedImmune might not repeat its $86 price peak any time soon, Mr. Wilson says, his 12-month price target on the stock is in the mid-$50s. vaccine ??????? sheeeeeees Stefaan